Kura Oncology to Participate in Stifel Targeted Oncology Forum
Kura Oncology (NASDAQ: KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced its upcoming participation in the Stifel 2025 Virtual Targeted Oncology Forum.
The company's President and CEO, Troy Wilson, Ph.D., J.D., will engage in a virtual fireside chat scheduled for April 8, 2025, at 10:30 a.m. ET / 7:30 a.m. PT. Investors and interested parties can access the live audio webcast through the Investors section of Kura's website, with a replay available after the event.
Kura Oncology (NASDAQ: KURA), un'azienda biofarmaceutica in fase clinica focalizzata su farmaci di precisione per il trattamento del cancro, ha annunciato la sua prossima partecipazione al Stifel 2025 Virtual Targeted Oncology Forum.
Il presidente e CEO dell'azienda, Troy Wilson, Ph.D., J.D., parteciperà a una chiacchierata virtuale programmata per l'8 aprile 2025, alle 10:30 ET / 7:30 PT. Gli investitori e le parti interessate possono accedere alla diretta audio tramite la sezione Investitori del sito web di Kura, con una registrazione disponibile dopo l'evento.
Kura Oncology (NASDAQ: KURA), una empresa biofarmacéutica en etapa clínica centrada en medicamentos de precisión para el tratamiento del cáncer, ha anunciado su próxima participación en el Stifel 2025 Virtual Targeted Oncology Forum.
El presidente y CEO de la empresa, Troy Wilson, Ph.D., J.D., participará en una charla virtual programada para el 8 de abril de 2025, a las 10:30 a.m. ET / 7:30 a.m. PT. Los inversores y partes interesadas pueden acceder a la transmisión de audio en vivo a través de la sección de Inversores del sitio web de Kura, con una repetición disponible después del evento.
Kura Oncology (NASDAQ: KURA), 암 치료를 위한 정밀 의약품에 중점을 둔 임상 단계의 생명공학 회사가 Stifel 2025 Virtual Targeted Oncology Forum에 참여할 예정이라고 발표했습니다.
회사의 사장 겸 CEO인 Troy Wilson, Ph.D., J.D.는 2025년 4월 8일 오전 10시 30분 ET / 오전 7시 30분 PT로 예정된 가상 대화에 참여할 것입니다. 투자자 및 이해관계자는 Kura 웹사이트의 투자자 섹션을 통해 실시간 오디오 웹캐스트에 접속할 수 있으며, 이벤트 후에 재생도 가능합니다.
Kura Oncology (NASDAQ: KURA), une entreprise biopharmaceutique en phase clinique axée sur les médicaments de précision pour le traitement du cancer, a annoncé sa prochaine participation au Stifel 2025 Virtual Targeted Oncology Forum.
Le président et PDG de l'entreprise, Troy Wilson, Ph.D., J.D., participera à une discussion virtuelle prévue pour le 8 avril 2025 à 10h30 ET / 7h30 PT. Les investisseurs et les parties intéressées peuvent accéder à la diffusion audio en direct via la section Investisseurs du site Web de Kura, avec une rediffusion disponible après l'événement.
Kura Oncology (NASDAQ: KURA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Präzisionsmedikamente zur Krebsbehandlung konzentriert, hat seine bevorstehende Teilnahme am Stifel 2025 Virtual Targeted Oncology Forum bekannt gegeben.
Der Präsident und CEO des Unternehmens, Troy Wilson, Ph.D., J.D., wird an einem virtuellen Gespräch teilnehmen, das für den 8. April 2025 um 10:30 Uhr ET / 7:30 Uhr PT geplant ist. Investoren und Interessierte können über den Bereich Investoren auf der Website von Kura auf das Live-Audio-Webcast zugreifen, mit einer Wiederholung, die nach der Veranstaltung verfügbar ist.
- None.
- None.
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Stifel 2025 Virtual Targeted Oncology Forum. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 10:30 a.m. ET / 7:30 a.m. PT on April 8, 2025. A live audio webcast of the fireside chat will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay following the event.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of relapsed/refractory (“R/R”) NPM1-mutant acute myeloid leukemia (“AML”). In November 2024, Kura Oncology entered a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Contacts
Investors:
Patti Bank
Managing Director
(415) 513-1284
patti.bank@icrhealthcare.com
Media:
Alexandra Weingarten
Associate Director, Corporate Communications
& Investor Relations
(858) 500-8822
alexandra@kuraoncology.com
FAQ
When is Kura Oncology (KURA) presenting at the Stifel 2025 Virtual Targeted Oncology Forum?
How can investors watch Kura Oncology's (KURA) presentation at the Stifel Oncology Forum?
What type of event will KURA's CEO participate in at the Stifel 2025 Forum?
What is Kura Oncology's (KURA) current business focus?
